Elutia (ELUT) Earnings Date & Reports

Key Takeaways

• Net sales from continuing operations rose 20.4% year over year to $1.1 million, led by 20% growth in the cardiovascular business.
• Total net loss narrowed to $1.3 million, or $0.03 per basic share, from $3.9 million a year earlier, helped by $5.2 million in income from discontinued operations.
• Loss from operations widened to $6.9 million, reflecting a $1.9 million increase in research and development (R&D) spending on the NXT-41 and NXT-41x programs.
• Elutia secured $26 million in non-dilutive capital across three completed funding catalysts and ended the quarter with $29.1 million in cash, excluding an $8 million Boston Scientific holdback received October 1.
• Management plans to submit NXT-41x to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026, with an FDA clearance decision on NXT-41 expected this quarter.
• For more information on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover Trending AI Robots to explore AI-driven trading signals and market ideas.

Earnings Context and Why It Matters

Elutia is in the middle of a strategic transformation into a pure-play drug-eluting biomatrix company focused on surgical reconstruction. Following the sale of its SimpliDerm business in August, the third quarter offered investors a clearer view of the leaner, cardiovascular-and-pipeline-focused company that remains. The report matters less for its headline revenue than for what it signals about Elutia's two critical near-term drivers: regulatory progress on its NXT-41 and NXT-41x programs and the strength of its cash position. With a $1.5 billion U.S. breast reconstruction market in view, investors are closely watching whether Elutia can fund itself without diluting shareholders while advancing its lead product toward FDA clearance.

Reported Results

For the third quarter ended September 30, 2026, Elutia reported net sales from continuing operations of $1.1 million, up 20.4% from $0.9 million a year earlier. Gross margin on a GAAP (Generally Accepted Accounting Principles) basis improved to 61.7% from 52.8%, while adjusted gross margin, which excludes non-cash amortization of intangibles, reached 85.5% compared with 81.3%.

Total operating expenses increased to $7.6 million from $6.4 million, driven by $1.9 million of additional R&D spending on NXT-41 and NXT-41x, partially offset by a $0.7 million reduction in net litigation costs. Loss from operations widened to $6.9 million from $5.9 million, and net loss from continuing operations was $6.5 million, compared with $1.0 million in the prior-year period, which had benefited from a $5.1 million non-cash warrant revaluation gain. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was a loss of $5.6 million, versus a loss of $3.4 million a year earlier.

On a total-company basis, income from discontinued operations of $5.2 million narrowed the net loss to $1.3 million, or $0.03 per basic share, from $3.9 million, or $0.09 per basic share, a year ago. Revenue came in below consensus expectations, which had reflected now-divested SimpliDerm sales, while the reported loss per share was narrower than the consensus estimate. Elutia ended the quarter with $29.1 million in cash and cash equivalents.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Elutia across the medical technology space, it can streamline research and surface actionable signals.

Market Reaction and Investor Sentiment

Elutia's earnings were not a single-line story. The headline revenue figure of $1.1 million fell well short of the roughly $3.0 million consensus, but much of that gap reflects the mid-quarter divestiture of SimpliDerm, which shifted that revenue into discontinued operations. At the same time, the reported loss per share was meaningfully narrower than the consensus estimate of about $0.13 to $0.15, helped by income from the divested business. Investors appear to be weighing these accounting-driven movements against the more durable positives: a strengthened balance sheet, reduced litigation costs, and clearer visibility into the NXT-41 and NXT-41x regulatory timeline. Sentiment remains focused on execution risk around FDA clearance and Elutia's ability to preserve its runway without further equity dilution.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important near-term catalyst is regulatory. Elutia expects an FDA clearance decision on NXT-41 during the current quarter and plans to submit NXT-41x to the agency in the fourth quarter of 2026, with a clearance decision anticipated in the first half of 2027. Investors should monitor the timing and outcome of both steps, since clearance would validate the company's drug-eluting biomatrix platform ahead of a commercial launch.

Funding remains a second focal point. The company completed three funding catalysts in just over seven weeks—a $15 million loan facility with Avenue Capital Group, the $8 million SimpliDerm sale to Cellution Biologics, and the $8 million Boston Scientific holdback—adding $26 million without an equity offering. Additional capital sources include a $5 million second tranche from Avenue Capital, up to $3 million in SimpliDerm milestone payments, and a potential sale of the cardiovascular business.

Finally, investors should watch operating trends in the cardiovascular segment, which grew revenue 20% year over year with an 85% adjusted gross margin, and any updates on the strategic divestiture process. Cost discipline and the pace of R&D investment will also shape how far the current cash runway extends as Elutia prepares for a potential commercial launch of NXT-41x.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations